A genetic mutation causing ISG15 deficiency increases vulnerability to bacterial infections while granting unusual antiviral abilities. Research by scientists at Columbia University led to the development of a new therapy using a nasal drip to administer an experimental drug that mimics these antiviral properties. Initial curiosity-led studies on patients with mild inflammation revealed their unique ability to resist viruses. The ongoing work aims to produce light immune activation to protect individuals from various viral infections, despite not knowing the specific virus involved.
The research reveals that ISG15 deficiency, while increasing vulnerability to bacterial infections, provides unique antiviral capabilities that can be harnessed through innovative therapies.
Bogunovic's study shows that patients with ISG15 mutation are prone to mild inflammation but have powerful resistance to various viruses, prompting new treatment possibilities.
Collection
[
|
...
]